AstraZeneca (LON:AZN) Given “Overweight” Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of AstraZeneca (LON:AZN) in a research note published on Wednesday morning, Marketbeat Ratings reports.

Several other brokerages also recently weighed in on AZN. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.76) price objective on shares of AstraZeneca in a research report on Monday, January 27th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of GBX 7,542.80 ($94.91).

AstraZeneca Price Performance

AZN stock opened at £117.04 ($147.28) on Wednesday. The business has a 50 day moving average price of £109.53 and a 200 day moving average price of £114.64. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The stock has a market cap of £225.19 billion, a price-to-earnings ratio of 32.08, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a fifty-two week low of GBX 9,670 ($121.68) and a fifty-two week high of £133.88 ($168.47).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.